SEARCH:   Advanced

Blood, 15 September 2006, Vol. 108, No. 6, pp. 1835-1840. Prepublished online as a Blood First Edition Paper on May 18, 2006; DOI 10.1182/blood-2006-02-004325. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-02-004325v1 108/6/1835    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kantarjian, H. M. Articles by Cortes, J. Search for Related Content PubMed PubMed Citation Articles by Kantarjian, H. M. Articles by Cortes, J. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Survival benefit with imatinib mesylate versus interferon-–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia Hagop M. Kantarjian, Moshe Talpaz, Susan O'Brien, Daniel Jones, Francis Giles, Guillermo Garcia-Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, and Jorge Cortes From the Departments of Leukemia, Experimental Therapeutics, and Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX. A survival benefit for imatinib mesylate versus interferon- therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)–positive chronic-phase chronic myelogenous leukemia (CML) due to the high rate of crossover (90%) from interferon- to imatinib mesylate within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib mesylate at our institution (2000-2004) to 650 patients treated with interferon- (1982-1997). The complete cytogenetic response rates were 87% with imatinib mesylate and 28% with interferon- (P < .001). The estimated 3-year survival rates were 96% with imatinib mesylate and 81% with interferon- (P < .01). Survival rates with imatinib mesylate were significantly better than with interferon- within each of the CML prognostic risks groups. By multivariate analysis, imatinib mesylate therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio, 0.44; P < .01). By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib mesylate or interferon-, suggesting that the survival benefit of imatinib mesylate (versus interferon- in newly diagnosed CML) is through improving cytogenetic response. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. de Lavallade, J. F. Apperley, J. S. Khorashad, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al. Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis J. Clin. Oncol., July 10, 2008; 26(20): 3358 - 3363. [Abstract] [Full Text] [PDF] H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods Blood, February 15, 2008; 111(4): 1774 - 1780. [Full Text] [PDF] D. L. White, V. A. Saunders, P. Dang, J. Engler, A. Venables, S. Zrim, A. Zannettino, K. Lynch, P. W. Manley, and T. Hughes Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood, December 1, 2007; 110(12): 4064 - 4072. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes Important Therapeutic Targets in Chronic Myelogenous Leukemia Clin. Cancer Res., February 15, 2007; 13(4): 1089 - 1097. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020